• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Amrix (Cyclobenzaprine Hydrochloride) Extended-Release Capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2013

Summary View

 

WARNINGS

  • The development of a potentially life-threatening serotonin syndrome has been reported with Cyclobenzaprine when used in combination with other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or monoamine oxidase (MAO) inhibitors…
 

PRECAUTIONS

Drug Interactions
  • Postmarketing cases of serotonin syndrome have been reported during combined use of AMRIX cyclobenzaprine and other drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), Tramadol, Bupropion, Meperidine, Verapamil, or monoamine oxidase (MAO) inhibitors.…